Cargando…
Dexmedetomidine ameliorates high‐fat diet‐induced nonalcoholic fatty liver disease by targeting SCD1 in obesity mice
Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no therapeutic drugs approved for this pathology. Insulin resistance (IR) is implicated both in pathogenesis of nonalcoholic fatty liver disease (NAFLD) and in disease progression from steatosis...
Autores principales: | Tao, Linfen, Guo, Xiaolong, Xu, Min, Wang, Yumeng, Xie, Wenhua, Chen, Hong, Ma, Mengyao, Li, Xi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753983/ https://www.ncbi.nlm.nih.gov/pubmed/33474802 http://dx.doi.org/10.1002/prp2.700 |
Ejemplares similares
-
Effects of Mogrosides on High-Fat-Diet-Induced Obesity and Nonalcoholic Fatty Liver Disease in Mice
por: Zhang, Xiaobing, et al.
Publicado: (2018) -
Ameliorative Potential of Tamarindus indica on High Fat Diet Induced Nonalcoholic Fatty Liver Disease in Rats
por: Sasidharan, Suja Rani, et al.
Publicado: (2014) -
Chitosan Oligosaccharide Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) in Diet-Induced Obese Mice
por: Qian, Minyi, et al.
Publicado: (2019) -
Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2
por: Qian, Xiaoli, et al.
Publicado: (2021) -
Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism
por: Zhou, Tingting, et al.
Publicado: (2023)